TOI (The Oncology Institute) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


TOI The Oncology Institute Inc TOI
56 GF Score
Price $5.11
GF Value $2.24
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

The Oncology Institute's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TOI vs CCRN, SRTA, CYH: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Care Facilities subindustry, The Oncology Institute's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Oncology Institute Margin of Safety % (DCF Earnings Based) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Margin of Safety % (DCF Earnings Based) falls into.


TOI
56GF Score
The Oncology Institute Inc TOI
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is The Oncology Institute (TOI) Overvalued in 2026?

Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued. The current stock price of $5.11 is trading 127.9% above its estimated GF Value™ of $2.24. GuruFocus considers The Oncology Institute to be Significantly Overvalued.

Key valuation signals for TOI:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $2.24 vs. price of $5.11 (127.9% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Oncology Institute Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOI

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.11
Price
$2.24
GF Value